Publication: 172

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

Citation:: Leuk Lymphoma vol 50 (10) 1589-96

Year:: 2009
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: Received

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 470
Children:: None

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:
Grants:: CA31946

Corr. Author:
Authors:: John C Byrd Bercedis L Peterson Kanti R Rai David Hurd Raymond Hohl Michael C Perry Jon Gockerman Sreenivasa Nattam Richard A Larson

Networks:

Study: CALGB-19901
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Adult, Aged, Alemtuzumab, Anti-Infective Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm, Antigens, CD, Antigens, Neoplasm, Bone Marrow Diseases, CD52 Antigen, Cohort Studies, Cytomegalovirus Infections, Feasibility Studies, Female, Glycoproteins, Humans, Hypotension, Infusions, Intravenous, Injections, Subcutaneous, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Proteins, Survival Analysis, Vidarabine